Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion

Diabetes, Obesity and Metabolism

Volumn 14, Issue 4, 2012, Pages 329-334

  Roix, J J ^a   Decrescenzo, G A ^a   Cheung, P H ^a   Ciallella, J R ^b   Sulpice, T ^c   Saha, S ^a   Halse, R ^a  

^a BioMed Valley Discoveries Inc   (United States)

^b EnVivo Pharmaceuticals Inc   (United States)

^c Prologue Biotech   (France)

Author keywords

Antidiabetic drug; Diabetes mellitus; Insulin secretion; Pharmacology

Indexed keywords

AMISULPRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PROLACTIN;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; INSULIN RELEASE; ISOMER; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST;

EID: 84858004935     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01529.x     Document Type: Article

References (24)

1. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003; 56: 164-170.
2. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007; 33: 169-175.
3. Tschoner A, Engl J, Laimer M et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007; 61: 1356-1370.
4. Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 2006; 8: 125-135.
5. Tschoner A, Engl J, Rettenbacher M et al. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry 2009; 42: 29-34.
6. McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004; 18: 933-956.
7. Rettenbacher MA, Hummer M, Hofer A et al. Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. J Psychopharmacol 2007; 21: 400-404.
8. Lin CC, Bai YM, Wang YC et al. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J Clin Psychopharmacol 2009; 29: 529-536.
9. Marchese G, Ruiu S, Casti P, Saba P, Gessa GL, Pani L. Effect of the amisulpride isomers on rat prolactinemia. Eur J Pharmacol 2002; 448: 263-266.
10. Kopecek M, Bares M, Svarc J, Dockery C, Horácek J. Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett 2004; 25: 419-422.
11. Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc Patient Saf 2010; 2: 205-211.
12. Castelli MP, Mocci I, Sanna AM, Gessa GL, Pani L. (-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors. Eur J Pharmacol 2001; 432: 143-147.
13. Seino S, Shibasaki T, Minami K. Pancreatic beta-cell signaling: toward better understanding of diabetes and its treatment. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 563-577.
14. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009; 8: 369-385.
15. Davidson JA. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med 2009; 76(Suppl. 5): S28-S38.
16. Schoemaker H, Claustre Y, Fage D et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 83-97.
17. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009; 205: 119-128.
18. Defronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011; 34: 789-794.
19. Cincotta AH, Tozzo E, Scislowski PW. Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci 1997; 61: 951-956.
20. de Leeuw van Weenen JE, Parlevliet ET, Maechler P et al. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol 2010; 79: 1827-1836.
21. Garcia-Tornadu I, Ornstein AM, Chamson-Reig A et al. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 2010; 151: 1441-1450.
22. Peuskens J, De Hert M, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 2007; 22: 145-152.
23. Berinder K, Nyström T, Höybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011; 14: 199-207.
24. Tuzcu A, Yalaki S, Arikan S, Gokalp D, Bahcec M, Tuzcu S. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary 2009; 12: 330-334.